VGLUT2 in Parkinson’s disease: an emerging therapeutic target
We discuss approaches to maximize VGLUT2-mediated dopamine neuron resiliency. This includes increasing the efficiency of vesicular sequestration of dopamine to decrease generation of cytotoxic reactive oxygen species and increasing levels of neuroprotective antioxidant glutathione. Taken together, VGLUT2-mediated pathways represent original directions to treat Parkinson's disease symptoms and modify disease progression.
Authors
- Zachary Freyberg (ORCID: https://orcid.org/0000-0001-6460-0118)
- Mary M. Torregrossa (ORCID: https://orcid.org/0000-0003-2083-0231)
- Emily M. Rocha (ORCID: https://orcid.org/0000-0003-2171-5104)
Institutions
- University of Pittsburgh (US)
Publication Details
- Journal
- Expert Opinion on Therapeutic Targets
- Published
- 2026-01-19
- DOI
- https://doi.org/10.1080/14728222.2026.2619754
- Primary Topic
- Parkinson's Disease Mechanisms and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00